ReviewOxidative medicine and cellular longevity2021
Understanding the Stony Bridge between Osteoporosis and Vascular Calcification: Impact of the FGF23/Klotho axis.
Review in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The FGF23/α-Klotho Axis in Postmenopausal Osteoporosis: Associations with Bone Mineral Density and Diagnostic Discrimination.Journal of clinical medicine · 2026Article
- Association between blood pressure and clinical outcomes in patients undergoing maintenance hemodialysis.BMC nephrology · 2026Article
- Smart biomaterials for skeletal aging repair and regeneration.Bone research · 2026Review
- Associations of FGF23 and Apelin-13 with osteoporosis and diabetic peripheral neuropathy in postmenopausal women with type 2 diabetes mellitus.Frontiers in medicine · 2026Article
- Klotho Protein: A Multifaceted Guardian of Healthy Aging and Its Therapeutic Potential.International journal of nanomedicine · 2025Review
- The association between serum soluble α-Klotho and thyroid profile among adults from NHANES 2007-2012.BMC endocrine disorders · 2024Article
- Fibroblast growth factor 23-mediated regulation of osteoporosis: Assessed via Mendelian randomization and in vitro study.Journal of cellular and molecular medicine · 2024Article
- Bone fracture is associated with incident myocardial infarction in long-term follow-up.BMC public health · 2024Article
- High blood pressure is associated with increased risk of future fracture, but not vice versa.Scientific reports · 2024Article
- Cellular senescence in skeletal disease: mechanisms and treatment.Cellular & molecular biology letters · 2023Review
- Kefir peptides attenuate atherosclerotic vascular calcification and osteoporosis in atherogenic diet-fedFrontiers in cell and developmental biology · 2023Article
- Critical illness and bone metabolism: where are we now and what is next?European journal of medical research · 2022Review
- Elucidating the relationship between dyslipidemia and osteoporosis: A multicenter, prospective cohort study protocol.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A relationship between osteoporosis (OP) and vascular calcification (VC) is now proposed. There are common mechanisms underlying the regulation of them. Fibroblast growth factor- (FGF-) 23 and Klotho are hormones associated with the metabolic axis of osteovascular metabolism. Most recently, it was suggested that the FGF23-klotho axis is associated with increasing incidence of fractures and is potentially involved in the progression of the aortic-brachial stiffness ratio. Herein, we discussed the potential role of the FGF23/Klotho axis in the pathophysiology of OP and VC. We want to provide an update review in order to allow a better understanding of the potential role of the FGF23/Klotho axis in comorbidity of OP and VC. We believe that a better understanding of the relationship between both entities can help in proposing new therapeutic targets for reducing the increasing prevalence of OP and VC in the aging population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.